Jamie Teal
Adult Health · Boardman, OHNPI 1861937302
Payments from drug & device makers
Across 383 payments — averaging $18.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$882
- Regeneron Healthcare Solutions, Inc.$832
- Harmony Biosciences LLC$492
- United Therapeutics Corporation$298
- Amgen$286
- plus $2K from 28 others
What the payments were for
- Food & beverage$6,74594%
- Education$4046%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 82 | $2,002 |
| GSK | 98 | $882 |
| Regeneron Healthcare Solutions, Inc. | 51 | $832 |
| Harmony Biosciences LLC | 22 | $492 |
| United Therapeutics Corporation | 14 | $298 |
| Amgen | 12 | $286 |
| Jazz Pharmaceuticals Inc. | 9 | $215 |
| Boehringer Ingelheim | 12 | $213 |
| Pulmonx Corporation | 3 | $198 |
| Sanofi | 7 | $181 |
| Mallinckrodt Hospital Products Inc. | 6 | $138 |
| Genentech USA, Inc. | 6 | $130 |
| Baxter Healthcare | 5 | $105 |
| Merck | 4 | $104 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $103 |
| Grifols USA, LLC | 5 | $92 |
| Viatris Specialty LLC | 5 | $91 |
| Axsome Therapeutics, Inc. | 3 | $90 |
| Novartis | 3 | $80 |
| Insmed, Inc. | 4 | $80 |
| Mylan Specialty L.p. | 5 | $79 |
| Avadel CNS Pharmaceuticals, LLC | 2 | $67 |
| Electromed, Inc. | 3 | $58 |
| CSL Behring | 2 | $43 |
| AbbVie | 2 | $41 |
| Actelion Pharmaceuticals US, Inc. | 2 | $40 |
| Inspire Medical Systems, Inc. | 2 | $40 |
| Verona Pharma, Inc. | 2 | $37 |
| Philips North America LLC | 2 | $31 |
| Pfizer | 2 | $31 |
| Teva Pharmaceuticals USA, Inc. | 1 | $22 |
| Inogen, Inc. | 1 | $17 |
| Fisher & Paykel Healthcare Inc | 1 | $16 |
| Phadia US Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$628
- TEZSPIRE$493
- FASENRA$493
- BREZTRI$345
- SYMBICORT$156
- IMFINZI$148
- CHARTIS CATHETER$127
- ZEPHYR DELIVERY CATHETER$127
- ZEPHYR ENDOBRONCHIAL VALVE$127
- PULMONX CHARTIS TABLET CONSOLE$127
How this compares
$7,149 in reported general payments places this provider in the 90th percentile of 1,184 adult health providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 293 | $215,707 |
| OfevNintedanib Esylate | 11 | $117,735 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 132 | $95,008 |
| Spiriva RespimatTiotropium Bromide | 135 | $84,658 |
| Dupixent PenDupilumab | 17 | $62,518 |
| Breo ElliptaFluticasone/Vilanterol | 106 | $53,225 |
| Dupixent SyringeDupilumab | 12 | $46,022 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 45 | $20,232 |
| SymbicortBudesonide/Formoterol Fumarate | 39 | $17,231 |
| DuleraMometasone/Formoterol | 25 | $10,818 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 19 | $9,245 |
| Spiriva HandihalerTiotropium Bromide | 13 | $9,017 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 243 | $6,868 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 35 | $6,212 |
| Ventolin HfaAlbuterol Sulfate | 45 | $2,804 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $882 | $289,163444 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $213 | $211,638165 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $2,002 | $112,238171 claims |
| MerckDulera | $104 | $10,81825 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,184 adult health providers in Ohio.
Other adult health in Boardman
- Teresa ShafferBoardman$102K
- Emily DuezBoardman$8K
- Bonnie MohlerCanton$338K
- Andrew GuinigundoCincinnati$215K
- Gabriella McCartyWestlake$177K
- Karen SteffeyLyndhurst$145K
- Marie ChambersCenterville$134K
- Susan FlickCleveland$131K
- Margaret TiktinCleveland$105K
- Jesse McClainYoungstown$79K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.